4-methyl-cyclohexane-1,2-diyldiamine | 2214-68-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-methyl-cyclohexane-1,2-diyldiamine
• 英文别名: 4-Methyl-cyclohexan-1,2-diyldiamin；3.4-Diamino-1-methyl-cyclohexan；1-methyl-3,4-diaminocyclohexane；4-methylcyclohexane-1,2-diamine
• CAS: 2214-68-8
• 化学式: C₇H₁₆N₂
• mdl: MFCD19203285
• 分子量: 128.217
• InChiKey: KKYGOXSPNXROTG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  52
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-methyl-cyclohexane-1,2-diyldiamine 、 苯甲酰氯 在 alkali 作用下， 生成 N.N'-Dibenzoyl-4-methyl-cyclohexan-trans-1.2-diamin
  参考文献：
  名称：

  Koetz; Nussbaum; Takens, Journal fur praktische Chemie (Leipzig 1954), 1914, vol. <2>90, p. 388

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 盐酸 、 tin(ll) chloride 作用下， 生成 4-methyl-cyclohexane-1,2-diyldiamine
  参考文献：
  名称：

  Koetz; Nussbaum; Takens, Journal fur praktische Chemie (Leipzig 1954), 1914, vol. <2> 90, p. 365

  摘要：

  DOI：

文献信息

• METHOD FOR PRODUCING CIS- AND TRANS-ENRICHED MDACH
  申请人：BASF SE

  公开号：US20170260115A1

  公开（公告）日：2017-09-14

  A process for preparing trans-enriched MDACH, including: distilling an MDACH starting mixture in the presence of an auxiliary, which is an organic compound having a molar mass of 62 to 500 g/mol, a boiling point at least 5° C. above the boiling point of cis,cis-2,6-diamino-1-methylcyclohexane, and 2 to 4 functional groups, each of which is independently an alcohol group or a primary, secondary or tertiary amino group. The MDACH starting mixture includes 0 to 100% by weight of 2,4-MDACH and 0 to 100% by weight of 2,6-MDACH, based on the total amount of MDACH present in the MDACH starting mixture. The MDACH starting mixture includes both trans and cis isomers. Trans-enriched MDACH includes 0 to 100% by weight of 2,4-MDACH and 0 to 100% by weight of 2,6-MDACH, where the proportion of trans isomers in the mixture is higher than the proportion of trans isomers in the MDACH starting mixture.

  制备富含反式异构体MDACH的方法，包括：在辅助剂的存在下蒸馏MDACH起始混合物，所述辅助剂是一种有着62至500克/摩尔的摩尔质量、沸点至少比顺式、顺式-2,6-二氨基-1-甲基环己烷的沸点高出至少5摄氏度，并且具有2至4个官能团，每个官能团独立地是醇基团或一级、二级或三级氨基团的有机化合物。MDACH起始混合物包括以MDACH起始混合物中MDACH总量为基础的0至100%重量的2,4-MDACH和0至100%重量的2,6-MDACH。MDACH起始混合物包括反式和顺式异构体。富含反式异构体的MDACH包括以2,4-MDACH和2,6-MDACH的0至100%重量为基础，其中混合物中反式异构体的比例高于MDACH起始混合物中反式异构体的比例。
• Methyl-substituted trans-1,2-cyclohexanediamines as new ligands for oxaliplatin-type complexes
  作者：Ladislav Habala、Claudia Dworak、Alexey A. Nazarov、Christian G. Hartinger、Sergey A. Abramkin、Vladimir B. Arion、Wolfgang Lindner、Mathea S. Galanski、Bernhard K. Keppler

  DOI：10.1016/j.tet.2007.10.069

  日期：2008.1

  different synthetic routes lead (i) by the synthesis of the compound via ortho-bromination of a substituted cyclohexanone followed by reaction with hydroxylamine and reduction by hydrogen, (ii) by addition of azide to cyclohexene mediated by manganese(III) acetate and reduction by hydrogen, or (iii) by trans-dihydroxylation of cyclohexene, and subsequent conversion into the respective mesylate or tosylate

  提出了三种不同的途径合成取代的反式-（±）-1,2-环己二胺作为奥沙利铂类化合物的新配体。不同的合成路线导致（i）通过取代环己酮的邻溴化合成化合物，然后与羟胺反应并用氢还原，（ii）通过将乙酸锰（III）介导的叠氮化物加到环己烯中并还原通过氢，或（iii）通过环己烯的反二羟基化，然后转化成各自的甲磺酸酯或甲苯磺酸酯，随后被叠氮化物取代，和在4-甲基-反式的情况下还原-（±）-1,2-环己二胺分别优选在赤道上，主要在轴向上或仅在赤道上或轴向上定向的4-甲基。
• [EN] MONOMALEIMIDE-FUNCTIONALIZED PLATINUM COMPOUNDS FOR CANCER THERAPY<br/>[FR] COMPOSÉS DE PLATINE À FONCTION MONOMALÉIMIDE POUR LE TRAITEMENT DU CANCER
  申请人：UNIV WIEN MED

  公开号：WO2017097986A1

  公开（公告）日：2017-06-15

  The present invention relates to novel monomaleimide-functionalized platinum compounds of formula (I), including in particular novel monomaleimide-functionalized oxaliplatin and carboplatin derivatives, as well as their use as medicaments, particularly for the treatment or prevention of cancer.

  本发明涉及一种新型单马来酰亚胺官能化铂化合物，其化学式为(I)，其中包括新型单马来酰亚胺官能化奥沙利铂和卡铂衍生物，以及它们作为药物的用途，特别是用于治疗或预防癌症。
• Tumor-inhibiting platinum (II) oxalate complexes
  申请人：Keppler Bernhard

  公开号：US20050143455A1

  公开（公告）日：2005-06-30

  A tumor-inhibiting platinum (II) oxalate complex and its use as a therapeutic agent are provided, in particular as a tumor-inhibiting medicament. The complex may be compounds of the general formula (I), wherein the substituents R 1 , R 1′ , R 2 , R 2′ , R 3 , R 3′ , R 4 , and R 4′ are independently selected from the group consisting of hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkenyl, unsubstituted or substituted aryl and unsubstituted or substituted alkylaryl radicals, the substituents R 5 , R 5′ , R 6 , and R 6′ are independently selected from the group consisting of hydrogen, unsubstituted or substituted alkyl, and unsubstituted or substituted alkenyl radicals, and wherein optionally in each case at least two of the substituents R 1 , R 1′ , R 2 , R 2′ , R 3 , R 3′ , R 4 , and R 4′ can form with one another at least one unsubstituted or substituted alkylene, unsubstituted or substituted alkenylene radical or an unsubstituted or substituted aromatic ring, and wherein optionally at least one of the carbon atoms of the cyclohexane ring bearing the substituents R 1 , R 1′ , R 2 , R 2′ , R 3 , R 3′ , R 4 , and R 4′ is replaced by a heteroatom, and if the heteroatom is oxygen, the substituents R 1 , R 1′ , R 2 , R 2′ , R 3 , R 3′ , R 4 , and R 4′ can additionally be hydroxy radicals, and pharmaceutically compatible salts of them, provided that at least one of the substituents R 1 , R 1′ , R 2 , R 2′ , R 3 , R 3′ , R 4 , or R 4′ is not equal to hydrogen and the substituents R 1 or R 1′ and R 4 or R 4′ do not form any unsubstituted C 1-2 -alkylene radical with one another.

  提供了一种抑制肿瘤的铂(II)草酸配合物及其作为治疗剂的用途，特别是作为抑制肿瘤的药物。该配合物可以是通式(I)的化合物，其中取代基R1、R1'、R2、R2'、R3、R3'、R4和R4'独立地选自氢、未取代或取代的烷基、未取代或取代的烯基、未取代或取代的环烷基、未取代或取代的环烯基、未取代或取代的芳基和未取代或取代的烷基芳基基团的群，取代基R5、R5'、R6和R6'独立地选自氢、未取代或取代的烷基和未取代或取代的烯基基团，且在每种情况下，至少两个取代基R1、R1'、R2、R2'、R3、R3'、R4和R4'可以彼此形成至少一个未取代或取代的烷基、未取代或取代的烯基或未取代或取代的芳香环基团，且可选地，环己烷环上承载取代基R1、R1'、R2、R2'、R3、R3'、R4和R4'的碳原子中至少有一个被杂原子取代，如果杂原子是氧，则取代基R1、R1'、R2、R2'、R3、R3'、R4和R4'还可以是羟基基团，并且其药学上兼容的盐，前提是至少有一个取代基R1、R1'、R2、R2'、R3、R3'、R4或R4'不等于氢，并且取代基R1或R1'和R4或R4'不彼此形成任何未取代的C1-2烷基。
• Cyanoethylation of cycloaliphatic vicinal primary diamines
  申请人：AIR PRODUCTS AND CHEMICALS, INC.

  公开号：EP1179526A2

  公开（公告）日：2002-02-13

  A process for the cyanoethylation of substituted cycloaliphatic vicinal diamines which comprises reacting acrylonitrile and a diamine in the presence water as catalyst. Cyanoethylated methylcyclohexylamines are readily prepared in the presence of water.

  一种取代环脂族代二胺的氰乙基化工艺，包括丙烯腈和二胺在有水作为催化剂的情况下发生反应。在有水存在的情况下，很容易制备氰乙基化甲基环己胺。